View Item 

Show simple item record

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study
dc.contributor.authorWang, Michaelen_US
dc.contributor.authorPopplewell, Leslie L.en_US
dc.contributor.authorCollins, Robert H.en_US
dc.contributor.authorWinter, Jane N.en_US
dc.contributor.authorGoy, Andreen_US
dc.contributor.authorKaminski, Mark S.en_US
dc.contributor.authorBartlett, Nancy L.en_US
dc.contributor.authorJohnston, Patrick B.en_US
dc.contributor.authorLister, Johnen_US
dc.contributor.authorFanning, Suzanne R.en_US
dc.contributor.authorTuscano, Joseph M.en_US
dc.contributor.authorBeck, J. Thaddeusen_US
dc.contributor.authorKaya, Hakanen_US
dc.contributor.authorRobeva, Annaen_US
dc.contributor.authorFan, Jennaen_US
dc.contributor.authorKlimovsky, Judithen_US
dc.contributor.authorCheung, Wingen_US
dc.contributor.authorCherfi, Azzeddineen_US
dc.contributor.authorO'Connor, Owen A.en_US
dc.date.accessioned2014-05-23T15:58:54Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-23T15:58:54Z
dc.date.issued2014-05en_US
dc.identifier.citationWang, Michael; Popplewell, Leslie L.; Collins, Robert H.; Winter, Jane N.; Goy, Andre; Kaminski, Mark S.; Bartlett, Nancy L.; Johnston, Patrick B.; Lister, John; Fanning, Suzanne R.; Tuscano, Joseph M.; Beck, J. Thaddeus; Kaya, Hakan; Robeva, Anna; Fan, Jenna; Klimovsky, Judith; Cheung, Wing; Cherfi, Azzeddine; O'Connor, Owen A. (2014). "Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study." British Journal of Haematology 165(4): 510-518.en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106815
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMantle Cell Lymphomaen_US
dc.subject.otherMammalian Target of Rapamycinen_US
dc.subject.otherEverolimusen_US
dc.subject.otherBortezomiben_US
dc.subject.otherRelapsed/Refractory Diseaseen_US
dc.titleEverolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106815/1/bjh12780.pdf
dc.identifier.doi10.1111/bjh.12780en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceMeric‐Bernstam, F., Akcakanat, A., Chen, H., Do, K.A., Sangai, T., Adkins, F., Gonzalez‐Angulo, A.M., Rashid, A., Crosby, K., Dong, M., Phan, A.T., Wolff, R.A., Gupta, S., Mills, G.B. & Yao, J. ( 2012 ) PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clinical Cancer Research, 18, 1777 – 1789.en_US
dc.identifier.citedreferenceAnsell, S.M., Inwards, D.J., Rowland, K.M. Jr, Flynn, P.J., Morton, R.F., Moore, D.F. Jr, Kaufmann, S.H., Ghobrial, I., Kurtin, P.J., Maurer, M., Allmer, C. & Witzig, T.E. ( 2008 ) Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer, 113, 508 – 514.en_US
dc.identifier.citedreferenceAnsell, S.M., Tang, H., Kurtin, P.J., Koenig, P.A., Inwards, D.J., Shah, K., Ziesmer, S.C., Feldman, A.L., Rao, R., Gupta, M., Erlichman, C. & Witzig, T.E. ( 2011 ) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a multi‐center phase 2 study. Lancet Oncology, 12, 361 – 368.en_US
dc.identifier.citedreferenceBjornsti, M.A. & Houghton, P.J. ( 2004 ) The TOR pathway: a target for cancer therapy. Nature Reviews – Cancer, 4, 335 – 348.en_US
dc.identifier.citedreferenceCheson, B.D. ( 2007 ) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematology and Oncology Clinics of North America, 21, 841 – 854.en_US
dc.identifier.citedreferenceCheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo‐Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. ( 1999 ) Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.en_US
dc.identifier.citedreferenceCivallero, M., Cosenza, M., Marcheselli, L., Pozzi, S. & Sacchi, S. ( 2012 ) NVP‐BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opinion on Investigational Drugs, 21, 1597 – 1606.en_US
dc.identifier.citedreferenceCohen, P.L., Kurtin, P.J., Donovan, K.A. & Hanson, C.A. ( 1998 ) Bone marrow and peripheral blood involvement in mantle cell lymphoma. British Journal of Haematology, 101, 302 – 310.en_US
dc.identifier.citedreferenceDal, C.J., Zancai, P., Terrin, L., Guidoboni, M., Ponzoni, M., Pavan, A., Spina, M., Bergamin, S., Rizzo, S., Tirelli, U., De Rossi, A., Doglioni, C. & Dolcetti, R. ( 2008 ) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 111, 5142 – 5151.en_US
dc.identifier.citedreferenceDi Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., Sasazuki, T., Shirasawa, S., Geuna, M., Frattini, M., Baselga, J., Gallicchio, M., Biffo, S. & Bardelli, A. ( 2010 ) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 120, 2858 – 2866.en_US
dc.identifier.citedreferenceDreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., Kluin‐Nelemans, J.C., Ladetto, M., Le Gouill, S., Iannitto, E., Pileri, S., Rodriguez, J., Schmitz, N., Wotherspoon, A., Zinzani, P. & Zucca, E. ( 2013 ) ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T‐cell lymphoma. Annals of Oncology, 24, 857 – 877.en_US
dc.identifier.citedreferenceFisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. ( 2006 ) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 – 4874.en_US
dc.identifier.citedreferenceGalimberti, S. & Petrini, M. ( 2010 ) Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Managagement and Research, 2, 181 – 189.en_US
dc.identifier.citedreferenceGoy, A., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Nasta, S., O'Connor, O.A., Shi, H., Boral, A.L. & Fisher, R.I. ( 2009 ) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time‐to‐event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 20, 520 – 525.en_US
dc.identifier.citedreferenceGoy, A., Sinha, R., Williams, M.E., Besisik, S.K., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T. & Witzig, T.E. ( 2013 ) Single‐agent lenalidomide in patients with mantle‐cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL‐001 (EMERGE) study. Journal of Clinical Oncology, 31, 3688 – 3695.en_US
dc.identifier.citedreferenceHaritunians, T., Mori, A., O'Kelly, J., Luong, Q.T., Giles, F.J. & Koeffler, H.P. ( 2007 ) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 21, 333 – 339.en_US
dc.identifier.citedreferenceHess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L. & Coiffier, B. ( 2009 ) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27, 3822 – 3829.en_US
dc.identifier.citedreferenceHess, G., Keller, U., Atta, J., Buske, C., Borchmann, P., Medler, C., Witzens‐Harig, M. & Dreyling, M.H. ( 2011 ) Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report of an ongoing phase I/II trial. Blood (ASH Annual Meeting Abstracts), 118, 2697.en_US
dc.identifier.citedreferenceIyer, G., Hanrahan, A.J., Milowsky, M.I., Al‐Ahmadie, H., Scott, S.N., Janakiraman, M., Pirun, M., Sander, C., Socci, N.D., Ostrovnaya, I., Viale, A., Heguy, A., Peng, L., Chan, T.A., Bochner, B., Bajorin, D.F., Berger, M.F., Taylor, B.S. & Solit, D.B. ( 2012 ) Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 221.en_US
dc.identifier.citedreferenceKatzenberger, T., Kienle, D., Stilgenbauer, S., Holler, S., Schilling, C., Mader, U., Puppe, B., Petzoldt, C., Sander, S., Bullinger, L., Stocklein, H., Kalla, J., Hartmann, E., Adam, P., Ott, M.M., Muller‐Hermelink, H.K., Rosenwald, A. & Ott, G. ( 2008 ) Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. British Journal of Haematology, 142, 538 – 550.en_US
dc.identifier.citedreferenceKim, A., Park, S., Lee, J.E., Jang, W.S., Lee, S.J., Kang, H.J. & Lee, S.S. ( 2012 ) The dual PI3K and mTOR inhibitor NVP‐BEZ235 exhibits anti‐proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia Research, 36, 912 – 920.en_US
dc.identifier.citedreferenceMartin, P. & Leonard, J. ( 2011 ) Is there a role for “watch and wait” in patients with mantle cell lymphoma? Seminars in Hematology, 48, 189 – 193.en_US
dc.identifier.citedreferenceNational Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology: Non‐Hodgkin's Lymphomas. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed June 27, 2013.en_US
dc.identifier.citedreferenceO'Connor, O.A., Moskowitz, C., Portlock, C., Hamlin, P., Straus, D., Dumitrescu, O., Sarasohn, D., Gonen, M., Butos, J., Neylon, E., Hamelers, R., Mac‐Gregor, C.B., Blumel, S., Zelenetz, A.D., Gordon, L., Wright, J.J., Vose, J., Cooper, B. & Winter, J. ( 2009 ) Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. British Journal of Haematology, 145, 34 – 39.en_US
dc.identifier.citedreferencePeponi, E., Drakos, E., Reyes, G., Leventaki, V., Rassidakis, G.Z. & Medeiros, L.J. ( 2006 ) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. American Journal of Pathology, 169, 2171 – 2180.en_US
dc.identifier.citedreferencePerez‐Galan, P., Dreyling, M. & Wiestner, A. ( 2011 ) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood, 117, 26 – 38.en_US
dc.identifier.citedreferenceRenner, C., Zinzani, P.L., Gressin, R., Klingbiel, D., Dietrich, P.Y., Hitz, F., Bargetzi, M., Mingrone, W., Martinelli, G., Trojan, A., Bouabdallah, K., Lohri, A., Gyan, E., Biaggi, C., Cogliatti, S., Bertoni, F., Ghielmini, M., Brauchli, P. & Ketterer, N. ( 2012 ) A multicenter phase II trial (SAKK 36/06) of single‐agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97, 1085 – 1091.en_US
dc.identifier.citedreferenceRizzatti, E.G., Falcão, R.P., Panepucci, R.A., Proto‐Siqueira, R., Anselmo‐Lima, W.T., Okamoto, O.K. & Zago, M.A. ( 2005 ) Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K‐AKT, WNT and TGFbeta signalling pathways. British Journal of Haematology, 130, 516 – 526.en_US
dc.identifier.citedreferenceRomaguera, J.E., Medeiros, L.J., Hagemeister, F.B., Fayad, L.E., Rodriguez, M.A., Pro, B., Younes, A., McLaughlin, P., Goy, A., Sarris, A.H., Dang, N.H., Samaniego, F., Brown, H.M., Gagneja, H.K. & Cabanillas, F. ( 2003 ) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer, 97, 586 – 591.en_US
dc.identifier.citedreferenceRosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller‐Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., Leblanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. & Staudt, L.M. ( 2003 ) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185 – 197.en_US
dc.identifier.citedreferenceRosich, L., Xargay‐Torrent, S., Lopez‐Guerra, M., Campo, E., Colomer, D. & Roue, G. ( 2012 ) Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clinical Cancer Research, 18, 5278 – 5289.en_US
dc.identifier.citedreferenceRudelius, M., Pittaluga, S., Nishizuka, S., Pham, T.H., Fend, F., Jaffe, E.S., Quintanilla‐Martinez, L. & Raffeld, M. ( 2006 ) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 108, 1668 – 1676.en_US
dc.identifier.citedreferenceSchatz, J.H. ( 2011 ) Targeting the PI3K/AKT/mTOR pathway in non‐Hodgkin's lymphoma: results, biology, and development strategies. Current Oncology Reports, 13, 398 – 406.en_US
dc.identifier.citedreferenceWeigelt, B., Warne, P.H. & Downward, J. ( 2011 ) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011, 3222 – 3233.en_US
dc.identifier.citedreferenceWitzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyrun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H. & Kaufmann, S.H. ( 2005 ) Phase II trial of single‐agent temsirolimus (CCI‐779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 2005, 5347 – 5356.en_US
dc.identifier.citedreferenceWitzig, T.E., Reeder, C.B., Laplant, B.R., Gupta, M., Johnston, P.B., Micallef, I.N., Porrata, L.F., Ansell, S.M., Colgan, J.P., Jacobsen, E.D., Ghobrial, I.M. & Habermann, T.M. ( 2011 ) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341 – 347.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh12780.pdf
Size:
195.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.